Autosomal dominant osteopetrosis revisited: Lessons from recent studies

European Journal of Endocrinology

Volumn 169, Issue 2, 2013, Pages

  Bollerslev, Jens ^a,b   Henriksen, Kim ^c   Nielsen, Morten Frost ^d,e   Brixen, Kim ^d,e   Van Hul, Wim ^f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORDIC BIOSCIENCE A S   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE CHANNEL BLOCKING AGENT; DENOSUMAB; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; ROMOSOZUMAB; SEROTONIN;

ALBERS SCHOENBERG DISEASE; BONE ATROPHY; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE STRUCTURE; CLCN7 GENE; CLINICAL FEATURE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; GLUCOSE METABOLISM; HIGH BONE MASS DISEASE; HUMAN; JAW OSTEONECROSIS; LIPID METABOLISM; LRP5 GENE; METABOLIC BONE DISEASE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; MUTATOR GENE; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; WNT SIGNALING PATHWAY;

BONE RESORPTION; CHLORIDE CHANNELS; CLINICAL TRIALS AS TOPIC; GENETIC ASSOCIATION STUDIES; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; OSTEOCLASTS; OSTEOPETROSIS;

EID: 84880962088     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0136     Document Type: Review

References (213)

1. Karshner RG. Osteopetrosis. American Journal of Roentgenology 1926 16 405.
2. Albers-Schonberg H. Rontgenbilder einer seltenen Knochenerkrankung. Munchener Medizinische Wochenschrift 1904 51 365.
3. Johnston CC Jr, Lavy N, Lord T, Vellios F, Merritt AD & Deiss WP Jr. Osteopetrosis. A clinical, genetic, metabolic, and morphologic study of the dominantly inherited, benign form. Medicine 1968 47 149-167. (doi:10.1097/00005792-196803000-00004)
4. Sato S, Zhu XL & Sly WS. Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients. PNAS 1990 87 6073-6076. (doi:10.1073/pnas.87.16. 6073)
5. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS & Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. PNAS 1983 80 2752-2756. (doi:10.1073/pnas.80.9.2752)
6. Sly WS, Whyte MP, Sundaram V, Tashian RE, Hewett-Emmett D, Guibaud P, Vainsel M, Baluarte HJ, Gruskin A & Al-Mosawi M. Carbonic anhydrase II deficiency in12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. New England Journal of Medicine 1985 313 139-145. (doi:10.1056/NEJM198 507183130302)
7. Whyte MP, Murphy WA, Fallon MD, Sly WS, Teitelbaum SL, McAlister WH & Avioli LV. Osteopetrosis, renal tubular acidosis and basal ganglia calcification in three sisters. American Journal of Medicine19806964-74.(doi:10. 1016/0002-9343(80)90501-X)
8. Andersen PE Jr & Bollerslev J. Heterogeneity of autosomal dominant osteopetrosis. Radiology 1987 164 223-225.
9. Bollerslev J & Andersen PE Jr. Radiological, biochemical and hereditary evidence of two types of autosomal dominant osteopetrosis. Bone 1988 9 7-13. (doi:10.1016/8756-3282(88) 90021-X)
10. Bollerslev J & Andersen PE Jr. Fracture patterns in two types of autosomal-dominant osteopetrosis. Acta Orthopaedica Scandinavica 1989 60 110-112. (doi:10.3109/17453678909150106)
11. Bollerslev J, Steiniche T, Melsen F & Mosekilde L. Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: A study of two radiological types. Bone 1989 10 19-24. (doi:10.1016/8756-3282 (89)90142-7)
12. Bollerslev J,Mosekilde L, Nielsen HK &Mosekilde L. Biomechanical competence of iliac crest trabecular bone in autosomal dominant osteopetrosis type I. Bone 1989 10 159-164. (doi:10.1016/8756-3282(89)90048-3)
13. Gram J, Antonsen S, Horder M & Bollerslev J. Elevated serum levels of creatine kinase BB in autosomal dominant osteopetrosis type II. Calcified Tissue International 1991 48 438-439. (doi:10.1007/BF02556458)
14. Bollerslev J. Autosomal dominant osteopetrosis: Bone metabolism and epidemiological, clinical, and hormonal aspects. Endocrine Reviews 1989 10 45-67. (doi:10.1210/edrv-10-1-45)
15. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. American Journal of Human Genetics 2003 72 763-771. (doi:10.1086/368277)
16. Whyte MP, Kempa LG, McAlister WH, Zhang F, Mumm S & Wenkert D. Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Schonberg disease (Chloride Channel 7 Deficiency Osteopetrosis) among the sclerosing bone disorders. Journal of Bone and Mineral Research 2010 25 2515-2526. (doi:10.1002/jbmr.130)
17. Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A, Longo M, Fortunati D, Ballanti P, Iacobini M, Luciani M et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: Implications for diagnosis and treatment. Journal of Medical Genetics 2006 43 315-325. (doi:10.1136/jmg.2005. 036673)
18. Del Fattore A, Cappariello A & Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone 2008 42 19-29. (doi:10.1016/j.bone.2007.08. 029)
19. Benichou OD, Laredo JD & de Vernejoul MC. Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): Clinical and radiological manifestations in 42 patients. Bone 2000 26 87-93. (doi:10.1016/S8756-3282(99) 00244-6)
20. Waguespack SG, Hui SL, Dimeglio LA & Econs MJ. Autosomal dominant osteopetrosis: Clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation. Journal of Clinical Endocrinology and Metabolism 2007 92 771-778. (doi:10.1210/jc.2006-1986)
21. Frost M, Andersen T, Gossiel F, Hansen S, Bollerslev J, Van HulW, Eastell R, Kassem M & Brixen K. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. Journal of Bone and Mineral Research 2011 26 1721-1728. (doi:10.1002/jbmr.376)
22. Grodum E, Gram J, Brixen K & Bollerslev J. Autosomal dominant osteopetrosis: Bone mineral measurements of the entire skeleton of adults in two different subtypes. Bone 1995 16 431-434.
23. Brockstedt H, Bollerslev J, Melsen F & Mosekilde L. Cortical bone remodeling in autosomal dominant osteopetrosis: A study of two different phenotypes. Bone 1996 18 67-72. (doi:10.1016/8756-3282(95)00424-6)
24. Bollerslev J, Grontved A & Andersen PE Jr. Autosomal dominant osteopetrosis: An otoneurological investigation of the two radiological types. Laryngoscope 1988 98 411-413. (doi:10.1288/ 00005537-198804000-00011)
25. Bilezikian JP. Osteonecrosis of the jaw-do bisphosphonates pose a risk? New England Journal of Medicine 2006 355 2278-2281. (doi:10.1056/NEJMp068157)
26. Marx RE, Sawatari Y, Fortin M & Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. Journal of Oral and Maxillofacial Surgery 2005 63 1567-1575. (doi:10.1016/ j.joms.2005.07.010)
27. Pazianas M & Abrahamsen B. Safety of bisphosphonates. Bone 2011 49 103-110. (doi:10.1016/j.bone.2011.01.003)
28. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S & Pendrys D. Osteonecrosis of the jaw: More research needed. Journal of Bone and Mineral Research 2006 21 1503-1505. (doi:10.1359/jbmr.060712)
29. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebocontrolled trial. Lancet 2012 379 39-46. (doi:10.1016/S0140- 6736(11)61226-9)
30. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of Oncology 2012 23 1341-1347. (doi:10.1093/annonc/mdr435)
31. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2007 22 1479-1491. (doi:10.1359/jbmr.0707onj)
32. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Man Z, Mellstrom D, Radominski SC et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. Journal of Bone and Mineral Research 2012 27 694-701. (doi:10.1002/jbmr.1479)
33. Reid IR & Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nature Reviews. Rheumatology 2012 8 90-96.
34. Bedi RS, Goel P, Pasricha N, Sachin & Goel A. Osteopetrosis-A rare entity with osteomyelitis. Annals of Maxillofacial Surgery 2011 1 155-159. (doi:10.4103/2231-0746.92783)
35. Podenphant J. Methodological problems in bone histomorphometry and its application in postmenopausal osteoporosis. Danish Medical Bulletin 1990 37 424-433.
36. Hasling C, Eriksen EF, Charles P & Mosekilde L. Exogenous triiodothyronine activates bone remodeling. Bone 1987 8 65-69. (doi:10.1016/8756-3282(87)90072-X)
37. Bollerslev J, Thomas S, Grodum E, Brixen K & Djoseland O. Collagen metabolism in two types of autosomal dominant osteopetrosis during stimulation with thyroid hormones. European Journal of Endocrinology 1995 133 557-563. (doi:10.1530/eje. 0.1330557)
38. Bollerslev J, Ueland T, Grodum E, Haug E, Brixen K & Djoseland O. Biochemical markers of bone metabolism in benign human osteopetrosis: A study of two types at baseline and during stimulation with triiodothyronine. European Journal of Endocrinology 1998 139 29-35. (doi:10.1530/eje.0.1390029)
39. Bollerslev J, Ueland T & Odgren PR. Serum levels of TGF-b and fibronectin in autosomal dominant osteopetrosis in relation to underlying mutations and well-described murine counterparts. Critical Reviews in Eukaryotic Gene Expression 2003 13 163-171. (doi:10.1615/CritRevEukaryotGeneExpr.v13.i24. 90)
40. Henriksen K, Gram J, Hoegh-Andersen P, Jemtland R, Ueland T, Dziegiel MH, Schaller S, Bollerslev J & Karsdal MA. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptorrelated protein 5 are normal in vitro, but have decreased resorption capacity in vivo. American Journal of Pathology 2005 167 1341-1348. (doi:10.1016/S0002-9440(10)61221-7)
41. Bollerslev J, Marks SC Jr, Pockwinse S, Kassem M, Brixen K, Steiniche T & Mosekilde L. Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 1993 14 865-869. (doi:10.1016/8756-3282(93)90316-3)
42. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK & Halleen JM. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clinical Chemistry 2004 50 883-890. (doi:10.1373/clinchem.2003.029355)
43. Bollerslev J, Ueland T, Landaas S & Marks SC Jr. Serum creatine kinase isoenzyme BB in mammalian osteopetrosis. Clinical Orthopaedics and Related Research 2000 377 241-247. (doi:10. 1097/00003086-200008000-00032)
44. Waguespack SG, Hui SL, White KE, Buckwalter KA & Econs MJ. Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers. Journal of Clinical Endocrinology and Metabolism 2002 87 2212-2217. (doi:10.1210/jc.87.5.2212)
45. Chalhoub N, Benachenhou N, Rajapurohitam V, Pata M, Ferron M, Frattini A, Villa A & Vacher J. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nature Medicine 2003 9 399-406. (doi:10.1038/nm842)
46. Wicking C &Williamson B. From linked marker to gene. Trends in Genetics 1991 7 288-293.
47. Balemans W, Van Wesenbeeck L & Van Hul W. A clinical and molecular overview of the human osteopetroses. Calcified Tissue International 2005 77 263-274. (doi:10.1007/s00223-005-0027-6)
48. Benichou O, Cleiren E, Gram J, Bollerslev J, de Vernejoul MC & Van HulW. Mapping of autosomal dominant osteopetrosis type II (Albers-Schonberg disease) to chromosome 16p13.3. American Journal of Human Genetics 2001 69 647-654. (doi:10.1086/ 323132)
49. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G & Jentsch TJ. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001 104 205-215. (doi:10.1016/S0092- 8674(01)00206-9)
50. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Human Molecular Genetics 2001 10 2861-2867. (doi:10.1093/ hmg/10.25.2861)
51. Leisle L, Ludwig CF, Wagner FA, Jentsch TJ & Stauber T. ClC-7 is a slowly voltage-gated 2Cl(K)/1H(C)-exchanger and requires Ostm1 for transport activity. EMBO Journal 2011 30 2140-2152. (doi:10.1038/emboj.2011.137)
52. Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J & Karsdal MA. Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. American Journal of Pathology 2004 164 1537-1545. (doi:10.1016/S0002-9440 (10)63712-1)
53. Henriksen K, Gram J, Neutzsky-Wulff AV, Jensen VK, Dziegiel MH, Bollerslev J & Karsdal MA. Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7. Biochemical and Biophysical Research Communications 2009 378 804-809. (doi:10.1016/j.bbrc.2008.11.145)
54. Schulz P, Werner J, Stauber T, Henriksen K & Fendler K. The G215R mutation in the ClK/HC-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS ONE 2010 5 e12585. (doi:10.1371/ journal.pone.0012585)
55. Chu K, Snyder R & EconsMJ. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties. Journal of Bone and Mineral Research 2006 21 1089-1097. (doi:10.1359/jbmr.060409)
56. Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M, Abinun M, Andolina M, Flanagan A, Horwitz EM, Mihci E et al. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. Journal of Bone and Mineral Research 2003 18 1740-1747. (doi:10.1359/ jbmr.2003.18.10.1740)
57. Bollerslev J. Osteopetrosis. A genetic and epidemiological study. Clinical Genetics 1987 31 86-90. (doi:10.1111/j.1399-0004. 1987.tb02774.x)
58. Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T et al. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. Journal of Bone and Mineral Research 2003 18 1513-1518. (doi:10.1359/jbmr.2003.18.8. 1513)
59. Campos-Xavier AB, Casanova JL, Doumaz Y, Feingold J, Munnich A & Cormier-Daire V. Intrafamilial phenotypic variability of osteopetrosis due to chloride channel 7 (CLCN7) mutations. American Journal of Medical Genetics. Part A 2005 133A 216-218. (doi:10.1002/ajmg.a.30490)
60. Chu K, Koller DL, Snyder R, Fishburn T, Lai D, Waguespack SG, Foroud T & Econs MJ. Analysis of variation in expression of autosomal dominant osteopetrosis type 2: Searching for modifier genes. Bone 2005 37 655-661. (doi:10.1016/j.bone. 2005.06.003)
61. Kornak U, Ostertag A, Branger S, Benichou O & de Vernejoul MC. Polymorphisms in the CLCN7 gene modulate bone density in postmenopausal women and in patients with autosomal dominant osteopetrosis type II. Journal of Clinical Endocrinology and Metabolism 2006 91 995-1000. (doi:10.1210/jc.2005- 2017)
62. Pettersson U, Albagha OM, Mirolo M, Taranta A, Frattini A, McGuigan FE, Vezzoni P, Teti A, Van Hul W, Reid DM et al. Polymorphisms of the CLCN7 gene are associated with BMD in women. Journal of Bone and Mineral Research 2005 20 1960-1967. (doi:10.1359/JBMR.050717)
63. Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. American Journal of Pathology 2005 166 467-476. (doi:10.1016/S0002-9440(10)62269-9)
64. Taranta A, Migliaccio S, Recchia I, Caniglia M, Luciani M, De Rossi G, Dionisi-Vici C, Pinto RM, Francalanci P, Boldrini R et al. Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. American Journal of Pathology 2003 162 57-68. (doi:10.1016/S0002-9440(10)63798- 4)
65. Ferron M,Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P & Karsenty G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010 142 296-308. (doi:10.1016/j.cell.2010.06.003)
66. Nielsen RH, Karsdal MA, Sorensen MG, Dziegiel MH & Henriksen K. Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival. Biochemical and Biophysical Research Communications 2007 360 834-839. (doi:10.1016/j.bbrc.2007.06.145)
67. Houde N, Chamoux E, Bisson M & Roux S. Transforming growth factor-b1 (TGF-b1) induces human osteoclast apoptosis by up-regulating Bim. Journal of Biological Chemistry 2009 284 23397-23404. (doi:10.1074/jbc.M109.019372)
68. Bollerslev J, Nielsen HK, Larsen HF & Mosekilde L. Biochemical evidence of disturbed bone metabolism and calcium homeostasis in two types of autosomal dominant osteopetrosis. Acta Medica Scandinavica 1988 224 479-483. (doi:10.1111/j.0954-6820. 1988.tb19614.x)
69. Henriksen K, Andreassen KV, Thudium CS, Gudmann KN, Moscatelli I, Cruger-Hansen CE, Schulz AS, Dziegiel MH, Richter J, Karsdal MA et al. A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts. Bone 2012 51 353-361. (doi:10.1016/j.bone.2012.06.007)
70. Henriksen K, Flores C, Thomsen JS, Bruel AM, Thudium CS, Neutzsky-Wulff AV, Langenbach GE, Sims N, Askmyr M, Martin TJ et al. Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength. PLoS ONE 2011 6 e27482. (doi:10.1371/journal.pone.0027482)
71. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, Faraggiana T, Yoneda T, Mundy GR, Boyce BF et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. Journal of Cell Biology 2000 151 311-320. (doi:10.1083/jcb.151.2.311)
72. Rzeszutek K, Sarraf F & Davies JE. Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth. Journal of Craniofacial Surgery 2003 14 301-307. (doi:10.1097/ 00001665-200305000-00007)
73. Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Helix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. Journal of Bone and Mineral Research 2004 19 1144-1153. (doi:10.1359/JBMR.040302)
74. Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, Liang X, Gowen M & Farina C. A selective inhibitor of the osteoclastic V-H(C)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. Journal of Clinical Investigation 2000 106 309-318. (doi:10.1172/ JCI6145)
75. Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C & Henriksen K. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochemical and Biophysical Research Communications 2008 366 483-488. (doi:10.1016/j.bbrc.2007. 11.168)
76. Pederson L, Ruan M, Westendorf JJ, Khosla S & Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. PNAS 2008 105 20764-20769. (doi:10.1073/pnas. 0805133106)
77. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T & Matsuo K. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metabolism 2006 4 111-121. (doi:10.1016/j.cmet.2006.05.012)
78. Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. American Journal of Human Genetics 2008 83 64-76. (doi:10.1016/j.ajhg. 2008.06.015)
79. Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B & Chambers TJ. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 2008 42 200-211. (doi:10.1016/j.bone. 2007.09.044)
80. Hayden JM, Mohan S & Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone 1995 17 93S-98S. (doi:10.1016/8756-3282(95)00186-H)
81. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C & Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity? Journal of Bone and Mineral Research 2007 22 487-494. (doi:10.1359/jbmr.070109)
82. Jones SJ, Gray C & Boyde A. Simulation of bone resorption-repair coupling in vitro. Anatomy and Embryology 1994 190 339-349. (doi:10.1007/ BF00187292)
83. Schwartz Z, Lohmann CH, Wieland M, Cochran DL, Dean DD, Textor M, Bonewald LF & Boyan BD. Osteoblast proliferation and differentiation on dentin slices are modulated by pretreatment of the surface with tetracycline or osteoclasts. Journal of Periodontology 2000 71 586-597. (doi:10.1902/jop.2000. 71.4.586)
84. Sheu TJ, Schwarz EM, O'Keefe RJ, Rosier RN & Puzas JE. Use of a phage display technique to identify potential osteoblast binding sites within osteoclast lacunae. Journal of Bone and Mineral Research 2002 17 915-922. (doi:10.1359/jbmr.2002. 17.5.915)
85. Neutzsky-Wulff AV, Karsdal MA & Henriksen K. Characterization of the bone phenotype in ClC-7-deficient mice. Calcified Tissue International 2008 83 425-437. (doi:10.1007/s00223-008-9185-7)
86. Neutzsky-Wulff AV, Sims NA, Supanchart C, Kornak U, Felsenberg D, Poulton IJ, Martin TJ, Karsdal MA & Henriksen K. Severe developmental bone phenotype in ClC-7 deficient mice. Developmental Biology 2010 344 1001-1010. (doi:10.1016/ j.ydbio.2010.06.018)
87. Walker DG. Osteopetrosis cured by temporary parabiosis. Science 1973 180 875. (doi:10.1126/science.180.4088.875)
88. Coccia PF, Krivit W, Cervenka J, Clawson C, Kersey JH, Kim TH, Nesbit ME, Ramsay NK, Warkentin PI, Teitelbaum SL et al. Successful bone-marrow transplantation for infantile malignant osteopetrosis. New England Journal of Medicine 1980 302 701-708. (doi:10.1056/NEJM198003273021301)
89. Sieff CA, Chessells JM, Levinsky RJ, Pritchard J, Rogers DW, Casey A, Muller K & Hall CM. Allogeneic bone-marrow transplantation in infantile malignant osteopetrosis. Lancet 1983 1 437-441. (doi:10.1016/S0140-6736(83) 91438-1)
90. Steward CG. Hematopoietic stem cell transplantation for osteopetrosis. Pediatric Clinics of North America 2010 57 171-180. (doi:10.1016/j.pcl.2009.11. 006)
91. Pangrazio A, Pusch M, Caldana E, Frattini A, Lanino E, Tamhankar PM, Phadke S, Lopez AG, Orchard P, Mihci E et al. Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: Report of 20 novel mutations. Human Mutation 2010 31 E1071-E1080. (doi:10.1002/humu.21167)
92. Key L, Carnes D, Cole S, Holtrop M, Bar-Shavit Z, Shapiro F, Arceci R, Steinberg J, Gundberg C & Kahn A. Treatment of congenital osteopetrosis with high-dose calcitriol. New England Journal of Medicine 1984 310 409-415. (doi:10.1056/ NEJM198402163100701)
93. Key LL Jr, Rodriguiz RM, Willi SM, Wright NM, Hatcher HC, Eyre DR, Cure JK, Griffin PP & Ries WL. Long-term treatment of osteopetrosiswithrecombinant humaninterferon g.NewEngland Journal of Medicine 1995 332 1594-1599. (doi:10.1056/ NEJM199506153322402)
94. Lo IN, Blair HC, Poliani PL, Marrella V, Ficara F, Cassani B, Facchetti F, Fontana E, Guerrini MM, Traggiai E et al. Osteopetrosis rescue upon RANKL administration to Rankl (K/K) mice: A new therapy for human RANKL-dependent ARO. Journal of Bone and Mineral Research 2012 27 2501-2510. (doi:10.1002/jbmr.1712)
95. Del Fattore A, Capannalo M, Rucci N & Teti A. New siRNA-based therapy for autosomal dominant osteopetrosis. Journal of Bone and Mineral Research 2010 25 (suppl 1) abstract # 150. (doi:10.1002/jbmr565025130325)
96. Henriksen K, Neutzsky-Wulff AV, Bonewald LF & Karsdal MA. Local communication on and within bone controls bone remodeling. Bone 2009 44 1026-1033. (doi:10.1016/j.bone. 2009.03.671)
97. Henriksen K, Bollerslev J, Everts V & Karsdal MA. Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocrine Reviews 2011 32 31-63. (doi:10.1210/er.2010-0006)
98. Tolar J, Teitelbaum SL & Orchard PJ. Osteopetrosis. New England Journal of Medicine 2004 351 2839-2849. (doi:10.1056/ NEJMra040952)
99. Kasper D, Planells-Cases R, Fuhrmann JC, Scheel O, Zeitz O, Ruether K, Schmitt A, Poet M, Steinfeld R, Schweizer M et al. Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO Journal 2005 24 1079-1091. (doi:10.1038/sj.emboj.7600576)
100. Thudium CS, Jensen VK, Karsdal MA & Henriksen K. Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption-A novel target for treatment of osteoporosis. Current Protein&Peptide Science 2012 13 141-151. (doi:10.2174/138920312800493133)
101. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC & Ince BA. Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. Journal of Bone and Mineral Research 2010 25 937-947.
102. Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial. Journal of Clinical Endocrinology and Metabolism 2013 98 571-580. (doi:10.1210/jc.2012-2972)
103. Eastell R, Walsh JS, Watts NB & Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone 20114982-88. (doi:10.1016/ j.bone.2011.02.011)
104. Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. Journal of Bone and Mineral Research 2011 26 242-251. (doi:10.1002/jbmr.212)
105. Pennypacker B, Shea M, Liu Q, Masarachia P, Saftig P, Rodan S, Rodan G & Kimmel D. Bone density, strength, and formation in adult cathepsin K (K/K) mice. Bone 2009 44 199-207. (doi:10.1016/j.bone.2008.08.130)
106. Van Hul E, Gram J, Bollerslev J, Van Wesenbeeck L, Mathysen D, Andersen PE, Vanhoenacker F & Van Hul W. Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. Journal of Bone and Mineral Research 2002 17 1111-1117. (doi:10.1359/jbmr.2002.17.6.1111)
107. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nature Genetics 2000 25 343-346. (doi:10.1038/ 77131)
108. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001 107 513-523. (doi:10.1016/S0092- 8674(01)00571-2)
109. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K & Lifton RP. High bone density due to a mutation in LDL-receptor-related protein 5. New England Journal of Medicine 2002 346 1513-1521. (doi:10.1056/ NEJMoa013444)
110. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. American Journal of Human Genetics 2002 70 11-19. (doi:10.1086/338450)
111. Johnson ML, Harnish K, Nusse R & Van Hul W. LRP5 and Wnt signaling: A union made for bone. Journal of Bone and Mineral Research 2004 19 1749-1757. (doi:10.1359/JBMR.040816)
112. Piters E, Boudin E & Van Hul W. Wnt signaling: A win for bone. Archives of Biochemistry and Biophysics 2008 473 112-116. (doi:10.1016/j.abb. 2008.03.006)
113. Balemans W, Devogelaer JP, Cleiren E, Piters E, Caussin E & Van Hul W. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. Journal of Bone and Mineral Research 2007 22 708-716. (doi:10.1359/jbmr.070211)
114. Pangrazio A, Boudin E, Piters E, Damante G, Lo Iacono N, D'Elia AV, Vezzoni P, Van Hul W, Villa A & Sobacchi C. Identification of the first deletion in the LRP5 gene in a patient with autosomal dominant osteopetrosis type I. Bone 2011 49 568-571. (doi:10.1016/j.bone.2011.05.006)
115. Whyte MP, Reinus WH & Mumm S. High-bone-mass disease and LRP5. New England Journal of Medicine 2004 350 2096-2099. (doi:10.1056/ NEJM200405133502017)
116. Bollerslev J, Wilson SG, Dick IM, Islam FM, Ueland T, Palmer L, Devine A & Prince RL. LRP5 gene polymorphisms predict bone mass and incident fractures in elderly Australian women. Bone 2005 36 599-606. (doi:10.1016/j.bone.2005.01.006)
117. van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, Kiel DP, Langdahl BL, Lips P, Ljunggren O et al. Largescale analysis of association between LRP5 and LRP6 variants and osteoporosis. Journal of the American Medical Association 2008 299 1277-1290. (doi:10.1001/jama.299.11.1277)
118. Monroe DG, McGee-Lawrence ME, Oursler MJ & Westendorf JJ. Update on Wnt signaling in bone cell biology and bone disease. Gene 2012 492 1-18. (doi:10.1016/j.gene.2011.10.044)
119. Bhat BM, Allen KM, Liu W, Graham J, Morales A, Anisowicz A, Lam HS, McCauley C, Coleburn V, Cain M et al. Structure-based mutation analysis shows the importance of LRP5b-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling. Gene 2007 391 103-112. (doi:10.1016/j.gene.2006.12.014)
120. Ai M, Holmen SL, Van Hul W, Williams BO & Warman ML. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Molecular and Cellular Biology 2005 25 4946-4955. (doi:10.1128/MCB. 25.12.4946-4955.2005)
121. Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML & Van Hul W. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcified Tissue International 2008 82 445-453. (doi:10.1007/s00223-008-9130-9)
122. Semenov MV & He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. Journal of Biological Chemistry 2006 281 38276-38284. (doi:10.1074/jbc.M609509200)
123. Bourhis E, Wang W, Tam C, Hwang J, Zhang Y, Spittler D, Huang OW, Gong Y, Estevez A, Zilberleyb I et al. Wnt antagonists bind through a short peptide to the first b-propeller domain of LRP5/6. Structure 2011 19 1433-1442. (doi:10.1016/j.str. 2011.07.005)
124. Balemans W, Van Den Ende J, Freire Paes-Alves A, Dikkers FG, Willems PJ, Vanhoenacker F, de Almeida-Melo N, Alves CF, Stratakis CA, Hill SC et al. Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. American Journal of Human Genetics 1999 64 1661-1669. (doi:10.1086/302416)
125. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Human Molecular Genetics 2001 10 537-543. (doi:10.1093/hmg/10.5.537)
126. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. American Journal of Human Genetics 2001 68 577-589. (doi:10.1086/ 318811)
127. Van Hul W, Balemans W, Van Hul E, Dikkers FG, Obee H, Stokroos RJ,
128. Beighton P, Davidson J, Durr L & Hamersma H. Sclerosteosis-an autosomal recessive disorder. Clinical Genetics 1977 11 1-7. (doi:10.1111/j.1399-0004.1977.tb01269.x)
129. Van Buchem FS, Hadders HN & Ubbens R. An uncommon familial systemic disease of the skeleton: Hyperostosis corticalis generalisata familiaris. Acta Radiologica 1955 44 109-120. (doi:10.3109/00016925509170789)
130. Niziolek PJ, Farmer TL, Cui Y, Turner CH, Warman ML & Robling AG. High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes. Bone 2011 49 1010-1019. (doi:10.1016/j.bone.2011. 07.034)
131. Westendorf JJ, Kahler RA & Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004 341 19-39. (doi:10.1016/j.gene.2004.06.044)
132. Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Minaur S et al. Germline mutations inWTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nature Genetics 2009 41 95-100. (doi:10.1038/ng.270)
133. Perdu B, Lakeman P, Mortier G, Koenig R, Lachmeijer A & Van Hul W. Two novel WTX mutations underscore the unpredictability of male survival in osteopathia striata with cranial sclerosis. Clinical Genetics 2011 80 383-388. (doi:10.1111/ j.1399-0004.2010.01553.x)
134. Perdu B, de Freitas F, Frints SG, SchoutenM, Schrander-Stumpel C, Barbosa M, Pinto-Basto J, Reis-Lima M, de Vernejoul MC, Becker K et al. Osteopathia striata with cranial sclerosis owing to WTX gene defect. Journal of Bone and Mineral Research 2010 25 82-90. (doi:10.1359/jbmr.090707)
135. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007 315 1278-1282. (doi:10.1126/science.1136370)
136. Wang YK, Sporle R, Paperna T, Schughart K & Francke U. Characterization and expression pattern of the frizzled gene Fzd9, the mouse homolog of FZD9 which is deleted inWilliams-Beuren syndrome. Genomics 1999 57 235-248. (doi:10.1006/geno. 1999.5773)
137. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell 2005 8 751-764. (doi:10.1016/ j.devcel.2005.02.017)
138. Kubota T, Michigami T & Ozono K. Wnt signaling in bone metabolism. Journal of Bone and Mineral Metabolism 2009 27 265-271. (doi:10.1007/s00774-009- 0064-8)
139. Li HX, Luo X, Liu RX, Yang YJ & Yang GS. Roles of Wnt/ b-catenin signaling in adipogenic differentiation potential of adipose-derived mesenchymal stem cells. Molecular and Cellular Endocrinology 2008 291 116-124. (doi:10.1016/j.mce.2008. 05.005)
140. Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM & Kassem M. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. Journal of Bone and Mineral Research 2007 22 1720-1731. (doi:10.1359/jbmr. 070721)
141. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL & Macdougald OA. Inhibition of adipogenesis by Wnt signaling. Science 2000 289 950-953. (doi:10.1126/ science.289.5481.950)
142. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA, Hartmann C, Li L, Hwang TH, Brayton CF et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. Journal of Cell Biology 2002 157 303-314. (doi:10.1083/jcb.200201089)
143. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B et al. High bone mass in mice expressing a mutant LRP5 gene. Journal of Bone and Mineral Research 2003 18 960-974. (doi:10.1359/jbmr.2003. 18.6.960)
144. Rodda SJ & McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006 133 3231-3244. (doi:10.1242/dev.02480)
145. Day TF, Guo X, Garrett-Beal L & Yang Y. Wnt/b-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Developmental Cell 2005 8 739-750. (doi:10.1016/j.devcel. 2005.03.016)
146. Sawakami K, Robling AG, Ai M, Pitner ND, Liu D,Warden SJ, Li J, Maye P, Rowe DW, Duncan RL et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. Journal of Biological Chemistry 2006 281 23698-23711. (doi:10.1074/jbc.M601000200)
147. Jahaveri B, DallasM, Zhao H, Bonewald L & JohnsomM. b-Catenin haploinsufficiency in osteocytes abolishes the osteogenic effect of mechanical loading. abstract Journal of Bone and Mineral Research 2011 26 (suppl 1) abstract # 1068. (doi:10.1002/jbmr584)
148. Bonewald LF & Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone 2008 42 606-615. (doi:10.1016/j.bone. 2007.12.224)
149. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL & Williams BO. Essential role of b-catenin in postnatal bone acquisition. Journal of Biological Chemistry 2005 280 21162-21168. (doi:10.1074/ jbc.M501900200)
150. Glass DA & Karsenty G. Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. Annals of the New York Academy of Sciences 2006 1068 117-130. (doi:10.1196/annals. 1346.015)
151. Marks SC Jr. Osteopetrosis in the toothless (t1) rat: Presence of osteoclasts but failure to respond to parathyroid extract or to be cured by infusion of spleen or bone marrow cells from normal littermates. American Journal of Anatomy 1977 149 289-297. (doi:10.1002/aja.1001490212)
152. Marks SC Jr. The basic and applied biology of tooth eruption. Connective Tissue Research 1995 32 149-157. (doi:10.3109/ 03008209509013718)
153. Marks SC Jr & Schroeder HE. Tooth eruption: Theories and facts. Anatomical Record 1996 245 374-393. (doi:10.1002/(SICI)1097-0185(199606)245: 2!374::AID-AR18O3.0.CO;2-M)
154. Popoff SN & Marks SC Jr. The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development. Bone 1995 17 437-445. (doi:10.1016/8756-3282(95)00347-4)
155. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF & Kneissel M. Osteocyte Wnt/b-catenin signaling is required for normal bone homeostasis. Molecular and Cellular Biology 2010 30 3071-3085. (doi:10.1128/MCB. 01428-09)
156. Ruan M, Pederson L, Hachfeld C, Thomson M, Prakash YS, Howe A, Williams B, Davey R, Khosla S, Westendorf J et al. Deletion of Wnt Receptors Lrp5 and Lrp6 or b-catenin in late osteoclast precursors differentially suppress osteoclast differentiation and bone metabolism. Journal of Bone and Mineral Research 2012 27 (Suppl 1) abstract 1047.
157. Liu M, Kurimoto P, Qing-Tian N, Warmington KS, Xiaodong L, Scott Simonet W & Zhu Ke H. Decreased osteoclastogenesis in bone marrow cells derived from ovariectomized rats treated with sclerostin antibody. Journal of Bone and Mineral Research 2012 27 (Suppl 1) abstract SA0404.
158. Osier LK, Popoff SN & Marks SC Jr. Osteopetrosis in the toothless rat: Failure of osteoclast differentiation and function. Bone and Mineral 1987 3 35-45.
159. Van Wesenbeeck L, Odgren PR, MacKay CA, D'Angelo M, Safadi FF, Popoff SN, Van HulW& Marks SC Jr. The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. PNAS 2002 99 14303-14308. (doi:10.1073/pnas.202332999)
160. Balemans W & Van Hul W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: A story of extremes. Endocrinology 2007 148 2622-2629. (doi:10.1210/ en.2006-1352)
161. Dormandy J, Bhattacharya M & van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive. Drug Safety 2009 32 187-202. (doi:10.2165/00002018-2009320 30-00002)
162. Lane NE & Yao W. Glucocorticoid-induced bone fragility. Annals of the New York Academy of Sciences 2010 1192 81-83. (doi:10.1111/j.1749-6632.2009. 05228.x)
163. Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone 2010 46 1486-1497. (doi:10.1016/j.bone.2010.02.018)
164. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G & Fiore CE. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilizationinduced bone loss. Journal of Clinical Endocrinology and Metabolism 2010 95 2248-2253. (doi:10.1210/jc.2010-0067)
165. Suetta C, Hvid LG, Justesen L, Christensen U, Neergaard K, Simonsen L, Ortenblad N, Magnusson SP, Kjaer M & Aagaard P. Effects of aging on human skeletal muscle after immobilization and retraining. Journal of Applied Physiology 2009 107 1172-1180. (doi:10.1152/japplphysiol.00290.2009)
166. Boyle WJ, Simonet WS & Lacey DL. Osteoclast differentiation and activation. Nature 2003 423 337-342. (doi:10.1038/ nature01658)
167. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ & Onyia JE. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001 142 4047-4054. (doi:10.1210/en.142.9.4047)
168. Mason JJ & Williams BO. SOST and DKK: Antagonists of LRP family signaling as targets for treating bone disease. Journal of Osteoporosis 2010 2010 460120. (doi:10.4061/2010/460120)
169. Krishnan V, Bryant HU & Macdougald OA. Regulation of bone mass by Wnt signaling. Journal of Clinical Investigation 2006 116 1202-1209. (doi:10.1172/JCI28551)
170. Moon RT, Kohn AD, De Ferrari GV & Kaykas A. WNT and b-catenin signalling: Diseases and therapies. Nature Reviews. Genetics 2004 5 691-701. (doi:10.1038/nrg1427)
171. Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, Haytko P, Cusick T, Ireland C, Jarantow SWet al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. Journal of Biological Chemistry 2010 285 40135-40147. (doi:10.1074/jbc.M110.166892)
172. Glantschnig H, Scott K, Hampton R, Wei N, McCracken P, Nantermet P, Zhao JZ, Vitelli S, Huang L, Haytko P et al. A ratelimiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. Journal of Pharmacology and Experimental Therapeutics 2011 338 568-578. (doi:10.1124/jpet.111.181404)
173. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R et al. Sclerostin antibody treatment increases bone formation, bonemass, and bone strength in a rat model of postmenopausal osteoporosis. Journal of Bone andMineral Research 2009 24 578-588. (doi:10.1359/jbmr. 081206)
174. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. Journal of Bone and Mineral Research 2010 25 2647-2656. (doi:10.1002/jbmr.182)
175. Lewiecki EM. Sclerostin monoclonal antibody therapy with AMG 785: A potential treatment for osteoporosis. Expert Opinion on Biological Therapy 2011 11 117-127. (doi:10.1517/14712598. 2011.540565)
176. Ominsky M, Niu Q-T, Kurimoto P & Ke H. Tissue level mechanism of increased bone formation by sclerostin antibody in male Cynomolgus monkeys. Journal of Bone and Mineral Research 2010 25 1174. (doi:10.1002/jbmr.14)
177. Padhi D, Jang G, Stouch B, Fang L & Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Journal of Bone and Mineral Research 2011 26 19-26. (doi:10.1002/jbmr.173)
178. Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM, Jackson MT, Cake MA, Read RA, Bateman JF, Sambrook PN et al. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis and Cartilage 2011 19 874-885. (doi:10.1016/j.joca.2011.04.014)
179. Power J, Poole KE, van Bezooijen R, Doube M, Caballero-Alias AM, Lowik C, Papapoulos S, Reeve J & Loveridge N. Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture. Journal of Bone and Mineral Research 2010 25 1867-1876. (doi:10.1002/jbmr.70)
180. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007 130 456-469. (doi:10.1016/j.cell.2007.05.047)
181. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere MC, Aja S, Hussain MA, Bruning JC et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010 142 309-319. (doi:10.1016/j.cell.2010.06.002)
182. Nakamura T, Toita H, Yoshimoto A, Nishimura D, Takagi T, Ogawa T, Takeya T & Ishida-Kitagawa N. Potential involvement of Twist2 and Erk in the regulation of osteoblastogenesis by HB-EGF-EGFR signaling. Cell Structure and Function 2010 35 53-61. (doi:10.1247/csf.10001)
183. Fernandez-Real JM, Izquierdo M, Ortega F, Gorostiaga E, Gomez-Ambrosi J, Moreno-Navarrete JM, Fruhbeck G, Martinez C, Idoate F, Salvador J et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. Journal of Clinical Endocrinology and Metabolism 2009 94 237-245. (doi:10.1210/ jc.2008-0270)
184. Iglesias P, Arrieta F, Pinera M, Botella-Carretero JI, Balsa JA, Zamarron I, Menacho M, Diez JJ, Munoz T & Vazquez C. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and b-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clinical Endocrinology 2011 75 184-188. (doi:10.1111/j.1365-2265.2011.04035.x)
185. Im JA, Yu BP, Jeon JY & Kim SH. Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clinica Chimica Acta 2008 396 66-69. (doi:10.1016/j.cca.2008. 07.001)
186. Pittas AG, Harris SS, Eliades M, Stark P & Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. Journal of Clinical Endocrinology and Metabolism 2009 94 827-832. (doi:10.1210/jc.2008-1422)
187. Shea MK, Gundberg CM, Meigs JB, Dallal GE, Saltzman E, Yoshida M, Jacques PF & Booth SL. g-Carboxylation of osteocalcin and insulin resistance in older men and women. American Journal of Clinical Nutrition 2009 90 1230-1235. (doi:10.3945/ajcn.2009.28151)
188. Yeap BB, Chubb SA, Flicker L, McCaul KA, Ebeling PR, Beilby JP & Norman PE. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. European Journal of Endocrinology 2010 163 265-272. (doi:10.1530/EJE-10-0414)
189. Gerdhem P, Isaksson A, Akesson K & Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporosis International 2005 16 1506-1512. (doi:10.1007/ s00198-005-1877-5)
190. Hwang YC, Jeong IK, Ahn KJ & Chung HY. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporosis International 2012 23 1337-1342. (doi:10.1007/s00198-011-1679-x)
191. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T, Ishimura E, Nakatsuka K, Shioi A & Morii H. Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporosis International 1999 9 525-531. (doi:10.1007/s001980050180)
192. Winhofer Y, Handisurya A, Tura A, Bittighofer C, Klein K, Schneider B, Bieglmayer C, Wagner OF, Pacini G, Luger A et al. Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus. Diabetes Care 2010 33 139-143. (doi:10.2337/dc09-1237)
193. Ueland T, Fougner SL, Godang K, Lekva T, Schurgers LJ, Scholz H, Halvorsen B, Schreiner T, Aukrust P & Bollerslev J. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 361-368. (doi:10.1210/jc.2009-0422)
194. Schafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ, Vittinghoff E, Palermo L, Bilezikian JP, Shoback DM & Black DM. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: Parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). Journal of Clinical Endocrinology and Metabolism 2011 96 E1982-E1989. (doi:10.1210/ jc.2011-0587)
195. Anastasilakis AD, Efstathiadou Z, Plevraki E, Koukoulis GN, Slavakis A, Kita M & Avramidis A. Effect of exogenous intermittent recombinant human PTH 1-34 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity. Hormone and Metabolic Research 2008 40 702-707. (doi:10.1055/s-2008-1078729)
196. Schwartz AV, Schafer AL, Grey A, Vittinghoff E, Palermo L, Lui LY, Wallace RB, Cummings SR, Black DM, Bauer DC et al. Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT and FREEDOM trials. Journal of Bone and Mineral Research 2013 28 1348-1354. (doi:10.1002/ jbmr.1865)
197. Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z & He X. A mechanism for Wnt coreceptor activation. Molecular Cell 2004 13 149-156. (doi:10.1016/S1097-2765(03)00484-2)
198. Kim DH, Inagaki Y, Suzuki T, Ioka RX, Yoshioka SZ, Magoori K, Kang MJ, Cho Y, Nakano AZ, Liu Q et al. A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E. Journal of Biochemistry 1998 124 1072-1076. (doi:10.1093/ oxfordjournals.jbchem.a022223)
199. Guo YF, Xiong DH, Shen H, Zhao LJ, Xiao P, Guo Y, Wang W, Yang TL, Recker RR & Deng HW. Polymorphisms of the lowdensity lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. Journal of Medical Genetics 2006 43 798-803. (doi:10.1136/jmg.2006.041715)
200. Riancho JA, Olmos JM, Pineda B,Garcia-Ibarbia C,Perez-NunezMI, NanDN,Velasco J,CanoA, Garcia-Perez MA, Zarrabeitia MT et al. Wnt receptors, bone mass, and fractures: Gene-wide association analysis of LRP5 and LRP6 polymorphisms with replication. European Journal of Endocrinology 2011 164 123-131. (doi:10.1530/EJE-10-0582)
201. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, Andrew T, Falchi M, Gwilliam R, Ahmadi KR et al. Bone mineral density, osteoporosis, and osteoporotic fractures: A genome-wide association study. Lancet 2008 371 1505-1512. (doi:10.1016/S0140-6736(08)60599-1)
202. Fujino T, Asaba H, Kang MJ, Ikeda Y, Sone H, Takada S, Kim DH, Ioka RX, Ono M, Tomoyori H et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. PNAS 2003 100 229-234. (doi:10.1073/pnas.0133792100)
203. Palsgaard J, Emanuelli B, Winnay JN, Sumara G, Karsenty G & Kahn CR. Crosstalk between insulin and Wnt signaling in preadipocytes: Role of Wnt co-receptor LDL receptor related protein-5 (LRP5). Journal of Biological Chemistry 2012 287 12016-12026. (doi:10.1074/jbc.M111.337048)
204. Saarinen A, Mayranpaa MK, Lehesjoki AE & Makitie O. Low-density lipoprotein receptor-related protein 5 (LRP5) variation in fracture prone children. Bone 2010 46 940-945. (doi:10.1016/j.bone.2009.12.022)
205. Gregson CL, Steel SA, O'Rourke KP, Allan K, Ayuk J, Bhalla A, Clunie G, Crabtree N, Fogelman I, Goodby A et al. 'Sink or swim': An evaluation of the clinical characteristics of individuals with high bone mass. Osteoporosis International 2012 23 643-654. (doi:10.1007/s00198-011-1603-4)
206. Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, Guo XE, Mann JJ, Balapure AK, Gershon MD et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nature Medicine 2010 16 308-312. (doi:10.1038/nm.2098)
207. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008 135 825-837. (doi:10.1016/j.cell.2008. 09.059)
208. Frost M, Andersen TE, Yadav V, Brixen K, Karsenty G & Kassem M. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. Journal of Bone and Mineral Research 2010 25 673-675. (doi:10.1002/jbmr.44)
209. Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, Robinson DR, Zhong Z, Matthes S, Jacobsen CM, Conlon RA et al. Lrp5 functions in bone to regulate bone mass. Nature Medicine 2011 17 684-691. (doi:10.1038/nm.2388)
210. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nature Genetics 2007 39 960-962. (doi:10.1038/ng2076)
211. McDonald MM, Morse A, Peacock L, Mikulec K, Schindeler A & Little DG. Characterization of the bone phenotype and fracture repair in osteopetrotic incisors absent rats. Journal of Orthopaedic Research 2011 29 726-733. (doi:10.1002/jor.21293)
212. Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, Perdu B, MacKay CA, Van Hul E, Timmermans JP, Vanhoenacker F et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. Journal of Clinical Investigation 2007 117 919-930. (doi:10.1172/JCI30328)
213. Segovia-Silvestre T, Neutzsky-Wulff AV, Sorensen MG, Christiansen C, Bollerslev J, Karsdal MA & Henriksen K. Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Human Genetics 2009 124 561-577. (doi:10.1007/s00439-008-0583-8)